Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin

Pain Practice

Volumn 11, Issue 6, 2011, Pages 528-539

  Gore, Mugdha ^a   Tai, Kei Sing ^a   Zlateva, Gergana ^b   Bala Chandran, Arthi ^b   Leslie, Douglas ^c  

^a Avalon Health Solutions Inc   (United States)

^b PFIZER INC   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetic; Diabetic neuralgia; Diabetic neuropathy; Gabapentin; Healthcare costs; Healthcare resource use; Neuralgia; Painful; Pregabalin

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DIABETIC NEUROPATHY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION;

EID: 80655149578     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00450.x     Document Type: Article

References (48)

1. Mohamadi A, Cooke DW. Type 2 diabetes mellitus in children and adolescents. Adolesc Med State Art Rev. 2010;21:103-119.
2. Kaufman F. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002;15(suppl 2):737-744.
3. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007. National Institutes of Health Publication 08-3892. Available at: (accessed August 26, 2010).
4. American Diabetes Association. Economic costs of diabetes in the U.S in 2007. Diabetes Care. 2008;31:596-615. (Erratum in: Diabetes Care. 2008;31;1271).
5. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
6. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, post-herpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45-56.
7. Benbow SJ, Wallymahmed ME, Macfarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998;91:733-737.
8. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982.
9. Stewart WF, Ricci JA, Chee E, Hirsch AG, Brandenburg N. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med. 2007;49:672-679.
10. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
11. Gore M, Brandenburg N, Hoffman D, Tai K-S, Stacey B. Burden of illness in painful diabetic peripheral neuropathy (DPN): the patients' perspective. J Pain. 2006;7:892-900.
12. Gore M, Brandenburg N, Dukes E, Hoffman D, Tai K-S, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
13. Hoffman DL, Sadosky A, Alvir J. Cross-national burden of painful diabetic peripheral neuropathy in Asia, Latin America, and the Middle East. Pain Pract. 2009;9:35-42.
14. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20:26-33.
15. Ritzwoller DP, Ellis JL, Korner EJ, Hartsfield CL, Sadosky A. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin. 2009;25:1319-1328.
16. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11:360-368.
17. ® [Pregabalin] Capsules Prescribing Information. New York, NY: Pfizer, Inc.; 2009 (April).
18. ® [Duloxetine Hydrochloride] Delayed Release Capsules Prescribing Information. Indianapolis, IN: Eli Lilly and Company; 2009 (November).
19. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
20. Dworkin RH, O'connor PW, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
21. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clinic Proc. 2006;81:S12-S25.
22. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-1169.
23. Finnerup N, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305.
24. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11:153-162.
25. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13-21.
26. Gore M, Dukes E, Rowbotham DJ, Tai K-S, Leslie DL. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain. 2007;11:652-664.
27. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15:e95-e102.
28. Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.
29. Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract. 2011;11:167-179.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
31. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
33. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
34. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143-149.
35. Aronow WS. Heart disease and aging. Med Clin North Am. 2006;90:849-862.
36. Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98:204-208.
37. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16(2 suppl):S101-S105.
38. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10:127-135.
39. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract. 2008;9:26.
40. Hartsfield CL, Korner EJ, Ellis JL, Raebel MA, Merenich J, Brandenburg N. Painful diabetic peripheral neuropathy in a managed care setting: patient identification prevalence estimates and pharmacy utilization patterns. Popul Health Manag. 2008;11:317-328.
41. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-R1051.
42. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
43. Jamison RN, Anderson KO, Peeters-Asdourian C, Ferrante FM. Survey of opioid use in chronic nonmalignant pain patients. Reg Anesth. 1994;19:225-230.
44. Donner B, Raber M, Zenz M, Strumpf M, Dertwinkel R. Experiences with the prescription of opioids: a patient questionnaire. J Pain Symptom Manage. 1998;15:231-234.
45. Weinstein SM, Laux LF, Thornby JI, et al. Physicians' attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J. 2000;93:479-487.
46. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain. 1994;59:201-208.
47. Bhamb B, Brown D, Hariharan J, Anderson J, Balousek S, Fleming MF. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22:1859-1865.
48. Streltzer J, Ziegler P, Johnson B. Cautionary guidelines for the use of opioids in chronic pain. Am J Addict. 2009;18:1-4.